Tuesday 13 October 2026
Export EDIT’s income statement to Excel — free account
Editas Medicine, Inc.
EDIT Healthcare Biotechnology
Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.
2.47
0.28
−10.18%
Follow EDIT
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 5 | 5 | 2 | 3 | 3 | 2 | 4 | 2 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
1.62 | 3.28 | 2.25 | 2.17 | 12.28 | 6.84 | (1.28) | (0.67) | (7.30) | (13.39) |
P/S ratio |
90.70 | 100.81 | 33.55 | 72.09 | 45.29 | 70.28 | 29.40 | 9.70 | 3.24 | 4.49 |
Altman Z″-Score (non-manufacturers) |
0.42 | 1.69 | 1.59 | 0.95 | 1.07 | 3.11 | (3.54) | (4.23) | (14.20) | (29.91) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(40.14) | (55.20) | 807.45 | 36.08 | (102.47) | (51.91) | (13.71) | (34.09) | (2.06) | (5.00) |
Beneish M-Score |
(3.16) | (0.54) | (2.01) | 16.96 | 4.42 | (4.56) | 18.81 | (0.16) | 7.05 | (2.46) |
P/B ratio |
4.08 | 6.65 | 4.54 | 5.64 | 10.44 | 3.24 | 1.61 | 2.17 | 0.78 | 6.67 |
Price to Tangible BV |
4.08 | 6.65 | 4.54 | 5.64 | 10.44 | 3.24 | 1.61 | 2.17 | 0.78 | 6.67 |
EV/Sales |
65.89 | 79.27 | 23.01 | 51.40 | 41.21 | 51.98 | 13.58 | 5.98 | (4.11) | 1.67 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.53 | 0.00 |
EV/Operating CF |
(7.94) | (115.56) | (16.08) | (25.95) | (20.79) | (8.11) | (1.51) | (3.54) | 0.63 | (0.41) |
EV/FCF |
(7.42) | (94.95) | (14.58) | (22.58) | (20.00) | (7.73) | (1.48) | (3.41) | 0.61 | (0.41) |
Quick Ratio |
5.60 | 8.99 | 10.28 | 7.63 | 7.01 | 10.67 | 5.81 | 5.27 | 3.71 | 3.50 |
Current Ratio |
5.66 | 9.05 | 10.44 | 7.74 | 7.20 | 10.82 | 5.94 | 5.39 | 3.75 | 3.54 |
Net Debt/EBITDA |
1.57 | 2.52 | 3.05 | 3.31 | 3.07 | 2.68 | 1.56 | 1.92 | 1.07 | 0.94 |
Debt/Assets |
15.31% | 8.96% | 7.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.26 | 0.16 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.03 | 0.05 | 0.08 | 0.04 | 0.17 | 0.04 | 0.03 | 0.15 | 0.08 | 0.15 |
Operating CF/Net income |
0.52 | 0.08 | 0.42 | 0.30 | 1.55 | 0.85 | 0.80 | 0.86 | 0.89 | 1.03 |
Capex/Depreciation |
(2.89) | (0.76) | (1.45) | (2.14) | (1.81) | (1.19) | (0.73) | (3.80) | (490.33) | (0.08) |
Interest Coverage |
1,567.55 | (122.63) | 346.73 | (1,028.63) | 8.29 | (113.75) | 174.75 | — | (114.68) | (25.93) |
| (377.64%) | (70.22%) | (49.50%) | (53.65%) | (35.36%) | (40.65%) | (48.22%) | (43.17%) | (98.10%) | (198.14%) | |
| (51.37%) | (39.95%) | (27.71%) | (28.79%) | (21.45%) | (30.80%) | (36.99%) | (30.24%) | (56.40%) | (60.61%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (224.39%) | (860.78%) | (406.90%) | 0.00% | 0.00% |
Return on Tangible Assets |
(50.00%) | (35.92%) | (29.00%) | (32.25%) | (30.94%) | (40.31%) | (70.60%) | (52.90%) | (104.64%) | (132.07%) |
Average Days of Receivables |
5.31 | 18.05 | 0.34 | 7.43 | 24.33 | 3.82 | 95.27 | 47.59 | 183.73 | 136.70 |
Research and Development Expense of Revenue |
941.33% | 605.76% | 283.85% | 471.96% | 174.13% | 557.89% | 887.57% | 227.40% | 616.60% | 222.00% |
Selling, General and Administrative Expense of Revenue |
764.28% | 367.88% | 172.25% | 314.43% | 74.48% | 298.24% | 358.69% | 89.16% | 222.77% | 123.16% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
280.32% | 170.19% | 83.28% | 132.69% | 25.52% | 169.90% | 148.61% | 25.34% | 66.28% | 24.68% |
Graham Net Nets |
0.17 | 0.12 | 0.18 | 0.15 | 0.06 | 0.21 | 0.35 | 0.25 | 0.78 | 0.03 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(17.78%) | (8.68%) | (10.24%) | (9.08%) | (2.85%) | (10.73%) | (38.03%) | (20.54%) | (226.77%) | (92.20%) |
Free Cash Flow Yield |
(9.78%) | (0.83%) | (4.71%) | (3.16%) | (4.55%) | (9.57%) | (31.31%) | (18.06%) | (209.54%) | (91.01%) |
Revenue per Share |
0.19 | 0.34 | 0.68 | 0.41 | 1.55 | 0.38 | 0.29 | 1.03 | 0.39 | 0.46 |
Operating CF per Share |
(1.56) | (0.23) | (0.97) | (0.81) | (3.07) | (2.42) | (2.58) | (1.74) | (2.55) | (1.86) |
Capex per Share |
(0.11) | (0.05) | (0.10) | (0.12) | (0.12) | (0.12) | (0.06) | (0.06) | (0.11) | 0.00 |
Free Cash Flow per Share |
(1.67) | (0.28) | (1.07) | (0.93) | (3.19) | (2.54) | (2.64) | (1.80) | (2.66) | (1.87) |
Cash per Share |
5.75 | 8.16 | 7.83 | 9.15 | 6.86 | 7.39 | 5.01 | 4.25 | 3.28 | 1.65 |
Shareholders Equity per Share |
4.18 | 5.16 | 5.01 | 5.25 | 6.72 | 8.19 | 5.25 | 4.60 | 1.63 | 0.31 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.18 | 5.16 | 5.01 | 5.25 | 6.72 | 8.19 | 5.25 | 4.60 | 1.63 | 0.31 |
Free Cash Flow |
(53.72) | (11.46) | (50.42) | (46.73) | (186.99) | (171.78) | (181.45) | (136.90) | (219.11) | (165.58) |
Working Capital |
154.10 | 295.49 | 338.88 | 403.88 | 360.88 | 460.43 | 296.64 | 277.61 | 212.09 | 117.65 |
Capital Expenditures |
(3.47) | (2.04) | (4.72) | (6.06) | (7.15) | (7.98) | (4.10) | (4.72) | (8.83) | (0.34) |
Net Current Asset Value |
92.61 | 167.02 | 190.55 | 217.40 | 240.07 | 383.47 | 203.11 | 190.77 | 82.00 | 4.65 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.53 | 0.00 |
Capex to Sales |
0.57 | 0.15 | 0.15 | 0.30 | 0.08 | 0.31 | 0.21 | 0.06 | 0.27 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.03 | 0.07 | 0.08 | 0.26 | 0.28 | 0.39 | 0.36 | 0.10 | 0.00 | 1.24 |
Cash ROIC |
(15.13%) | (2.01%) | (7.91%) | (6.49%) | (23.50%) | (16.31%) | (25.74%) | (20.37%) | (54.21%) | (95.20%) |
Accounts Receivable Turnover |
10.94 | 35.80 | 90.09 | 91.66 | 28.06 | 8.09 | 7.28 | 10.19 | 2.44 | 2.58 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.55 | 0.38 | 0.35 | 0.22 | 3.23 | 3.16 | 2.71 | 7.67 | 13.23 | 15.72 |
Average Payables |
3.01 | 4.33 | 4.67 | 5.59 | 6.13 | 5.73 | 7.28 | 8.89 | 6.88 | 4.05 |
Average Assets |
189.27 | 301.22 | 396.82 | 464.64 | 540.74 | 625.04 | 595.90 | 506.74 | 420.37 | 264.06 |
Average Common Equity |
25.75 | 171.34 | 222.12 | 249.30 | 328.01 | 473.61 | 457.16 | 354.89 | 241.69 | 80.78 |
Columns are period end dates